1. Home
  2. ROIV vs LNTH Comparison

ROIV vs LNTH Comparison

Compare ROIV & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

N/A

Current Price

$40.14

Market Cap

25.1B

Sector

Health Care

ML Signal

N/A

Logo Lantheus Holdings Inc.

LNTH

Lantheus Holdings Inc.

N/A

Current Price

$100.70

Market Cap

6.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ROIV
LNTH
Founded
2014
1956
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.1B
6.6B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
ROIV
LNTH
Price
$40.14
$100.70
Analyst Decision
Strong Buy
Buy
Analyst Count
9
6
Target Price
$28.94
$87.00
AVG Volume (30 Days)
8.2M
1.1M
Earning Date
05-28-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.91
Revenue
$8,260,000.00
$343,374,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$744.61
$14.19
P/E Ratio
N/A
$34.62
Revenue Growth
N/A
3.62
52 Week Low
$13.94
$49.67
52 Week High
$42.50
$111.86

Technical Indicators

Market Signals
Indicator
ROIV
LNTH
Relative Strength Index (RSI) 60.38 47.80
Support Level $33.15 $100.51
Resistance Level $42.50 $101.43
Average True Range (ATR) 1.51 0.47
MACD 0.42 0.08
Stochastic Oscillator 67.36 45.10

Price Performance

Historical Comparison
ROIV
LNTH

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About LNTH Lantheus Holdings Inc.

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.

Share on Social Networks: